Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 11 of 11 results for pioglitazone + metformin

  1. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA583

  2. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    27 March 2019
    View recommendations

    Sections for TA572

  3. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

    NICE guideline
    Last updated
    29 June 2022
    View recommendations

    Sections for NG28

  4. Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA418

  5. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

    Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    25 May 2016
    View recommendations

    Sections for TA390

  6. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Last updated
    23 November 2016
    View recommendations

    Sections for TA288

  7. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    25 June 2014
    View recommendations

    Sections for TA315

  8. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    25 October 2023
    View recommendations

    Sections for TA924

  9. Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

    Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

    Evidence summary
    Published
    3 July 2015

  10. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 September 2013

  11. Three new treatment options for type 2 diabetes recommended by NICE

    Tens of thousands of people with type 2 diabetes will be eligible for new treatments under new guidance from NICE.

    News
    Published
    25 May 2016